NAD+ 1000 mg
Latest certified batch 2607150833Redox cofactor
VAT included. Delivery €NaN flat.
This listing is not currently available to order.
| Molecular target | Redox cofactor |
|---|---|
| Molecular class | Dinucleotide |
| Product grade | Analytical reference standard |
| Format | Lyophilised powder, sealed vial |
| Vial content | 1000 mg |
Single-vial pricing
| Purity, HPLC (area %), mean of 2 vials | 99.66% |
|---|---|
| Measured content, per vial, mean of 2 vials | 1091.41 mg |
| Vials assayed | 2 |
| Laboratory | Freedom Diagnostics |
| Assayed | 18 Jul 2026 |
The certificate for batch 2607150833, as Freedom Diagnostics issued it. Contact details, the laboratory's reference and its code are masked. More on the certificates
Every batch we ship assays at 98.0% or higher by RP-HPLC and holds 90% of its labelled mass or more, or we refund the order and the cost of the test. How the guarantee works
Specification and appearance
Storage and stability
- 2–8 °C, sealed and unopened — months.
- Keep dry and in the dark; UV degrades peptides fastest.
- −20 °C or below for long-term storage — years. Avoid repeated freeze–thaw cycles.
Batch archive
Every batch of this vial an independent laboratory has certified, so material already in storage stays traceable to the certificate it was released against.
- Batch 2607150833 — analysed 18 Jul 2026 — 99.66% — current
- Batch ND1000-26-004 — analysed 10 Jul 2026 — certificate
- Batch NAD1000-26-02 — analysed 25 Mar 2026 — certificate
- Batch NAD1000-2026-01 — analysed 25 Feb 2026 — certificate
Selected literature
A neutral bibliography for this molecule. Purivor makes no statement about what these papers say — the citations are provided so you can read the primary sources yourself.
- Coskun T. et al. (2018). LY3298176, a novel dual GIP and GLP-1 receptor agonist: from discovery to clinical proof of concept. Molecular Metabolism, 18, 3–14. DOI 10.1016/j.molmet.2018.09.009
- Willard F. S. et al. (2020). Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight, 5(17), e140532. DOI 10.1172/jci.insight.140532